{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:49:33Z","timestamp":1784677773070,"version":"3.55.0"},"reference-count":93,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Over the past 20 years, advances in the field of pathogenesis have inspired researchers to\nlook into novel pharmacological therapeutics that are more focused on the pathophysiological events\nof the disease (AD). This review article discussed the prior use of statins for the prevention of Alzheimer's\ndisease, which can help prevent the disease. Other drugs, such as memantine and donepezil, are\navailable, but they cannot prevent the onset of AD in middle age. Based on available clinical data, the\nvaluable effects of statins are mediated by alteration of \u03b2-amyloid (A\u03b2) and tau metabolism, genetic\nand lifestyle risk factors, along with other clinical aspects of AD. These findings suggested that using\nstatins in middle age may help to prevent Alzheimer's disease by modifying genetic and non-genetic\nrisk factors in later stages of life. In the present review, we elaborated upon the modification of risk\nfactors and amyloid metabolism in the development and progression of AD and their modulation\nthrough atorvastatin. Future directions in the research and treatment of Alzheimer's disease patients\ninclude the use of antisense oligonucleotides (ASO) to change target expression, and researchers discovered\ndecreased markers of oxidative stress in tissues affected by tau pathology in response to RNA\ninterference treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871527322666221005124808","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T11:28:26Z","timestamp":1665055706000},"page":"1462-1471","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Atorvastatin's Reduction of Alzheimer's Disease and Possible Alteration\nof Cognitive Function in Midlife as well as its Treatment"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6748-2137","authenticated-orcid":true,"given":"Umang","family":"Shah","sequence":"first","affiliation":[{"name":"Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (CHARUSAT), CHARUSAT\nCampus, Changa 388421, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneri","family":"Shah","sequence":"additional","affiliation":[{"name":"Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (CHARUSAT), CHARUSAT\nCampus, Changa 388421, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, L. M. College of Pharmacy, Ahmedabad, Gujarat,\nIndia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkesh","family":"Patel","sequence":"additional","affiliation":[{"name":"Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (CHARUSAT), CHARUSAT\nCampus, Changa 388421, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Patel","sequence":"additional","affiliation":[{"name":"Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (CHARUSAT), CHARUSAT\nCampus, Changa 388421, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilay","family":"Solanki","sequence":"additional","affiliation":[{"name":"Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (CHARUSAT), CHARUSAT\nCampus, Changa 388421, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swayamprakash","family":"Patel","sequence":"additional","affiliation":[{"name":"Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (CHARUSAT), CHARUSAT\nCampus, Changa 388421, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Patel","sequence":"additional","affiliation":[{"name":"Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (CHARUSAT), CHARUSAT\nCampus, Changa 388421, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Patel","sequence":"additional","affiliation":[{"name":"Indukaka Ipcowala College of Pharmacy, CVM University, VV Nagar, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavesh","family":"Patel","sequence":"additional","affiliation":[{"name":"Senior Research Scientist,\nNavinta LLC, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/7361613","volume":"2016","author":"Singh S.K.","year":"2016","unstructured":"Singh S.K.; Srivastav S.; Yadav A.K.; Srikrishna S.; Perry G.; Overview of Alzheimer\u2019s disease and some therapeutic approaches targeting A\u03b2 by using several synthetic and herbal compounds. Oxid Med Cell Longev 2016,2016,1-22","journal-title":"Oxid Med Cell Longev"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2174\/1871527319666200526144141","volume":"19","author":"Shah H.","year":"2020","unstructured":"Shah H.; Patel A.; Parikh V.; The \u03b2-Secretase Enzyme BACE1: A biochemical enigma for Alzheimer\u2019s Disease. CNS Neurol Disord Drug Targets 2020,19(3),184-194","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/alz.12638","volume":"18","year":"2022","unstructured":"2022 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 2022,18(4),700-789","journal-title":"Alzheimers Dement"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/nano11010059","volume":"11","author":"Agarwal M.","year":"2020","unstructured":"Agarwal M.; Alam M.R.; Haider M.K.; Malik M.Z.; Kim D.K.; Alzheimer\u2019s Disease: An overview of major hypotheses and therapeutic options in nanotechnology. Nanomaterials 2020,11(1),59","journal-title":"Nanomaterials"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3233\/JAD-2006-10408","volume":"10","author":"Riekse R.G.","year":"2006","unstructured":"Riekse R.G.; Li G.; Petrie E.C.; Effect of statins on Alzheimer\u2019s disease biomarkers in cerebrospinal fluid. J Alzheimers Dis 2006,10(4),399-406","journal-title":"J Alzheimers Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1008-1050","volume":"14","author":"Endo A.","year":"2008","unstructured":"Endo A.; A gift from nature: The birth of the statins. Nat Med 2008,14(10),1050-1052","journal-title":"Nat Med"},{"key":"ref=7","first-page":"1479","volume":"20","author":"Sharma K.","year":"2019","unstructured":"Sharma K.; Cholinesterase inhibitors as Alzheimer\u2019s therapeutics. (Review). Mol Med Rep 2019,20(2),1479-1487","journal-title":"Mol Med Rep"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","volume":"67","author":"Kumar A.","year":"2015","unstructured":"Kumar A.; Singh A.; Ekavali. A review on Alzheimer\u2019s disease pathophysiology and its management: an update. Pharmacol Rep 2015,67(2),195-203","journal-title":"Pharmacol Rep"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ejmech.2019.02.012","volume":"167","author":"AlFadly E.D.","year":"2019","unstructured":"AlFadly E.D.; Elzahhar P.A.; Tramarin A.; Tackling neuroinflammation and cholinergic deficit in Alzheimer\u2019s disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase. Eur J Med Chem 2019,167,161-186","journal-title":"Eur J Med Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9758\/cpn.2017.15.1.1","volume":"15","author":"Kocahan S.","year":"2017","unstructured":"Kocahan S.; Do\u011fan Z.; Mechanisms of Alzheimer\u2019s disease pathogenesis and prevention: The brain, neural pathology, N-methyl-D-aspartate receptors, tau protein and other risk factors. Clin Psychopharmacol Neurosci 2017,15(1),1-8","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.20510\/ukjpb\/7\/i1\/182376","volume":"7","author":"Mshimesh B.A.R.","year":"2019","unstructured":"Mshimesh B.A.R.; Al-Sudani B.T.; Jasim S.Y.; Correlation between biochemical and immunological alterations with updated therapies in Alzheimer\u2019s disease: A review article. Pharm Biosci J 2019,7(1),31-41","journal-title":"Pharm Biosci J"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2174\/1570159X15666170720095240","volume":"16","author":"Fakhoury M.","year":"2018","unstructured":"Fakhoury M.; Microglia and astrocytes in Alzheimer\u2019s disease: Implications for therapy. Curr Neuropharmacol 2018,16(5),508-518","journal-title":"Curr Neuropharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","volume":"34","author":"O\u2019Brien R.J.","year":"2011","unstructured":"O\u2019Brien R.J.; Wong P.C.; Amyloid precursor protein processing and Alzheimer\u2019s disease. Annu Rev Neurosci 2011,34(1),185-204","journal-title":"Annu Rev Neurosci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"fso.15.9","DOI":"10.4155\/fso.15.9","volume":"1","author":"MacLeod R","year":"2015","unstructured":"MacLeod R; Hillert EK; Cameron RT; Baillie GS; The role and therapeutic targeting of \u03b1-, \u03b2- and \u03b3-secretase in Alzheimer\u2019s disease. Future Sci OA 2015,1(3),fso.15.9","journal-title":"Future Sci OA"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"33923","DOI":"10.1074\/jbc.M105410200","volume":"276","author":"Scheuermann S.","year":"2001","unstructured":"Scheuermann S.; Hambsch B.; Hesse L.; Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer\u2019s disease. J Biol Chem 2001,276(36),33923-33929","journal-title":"J Biol Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fnins.2018.00025","volume":"12","author":"Kametani F.","year":"2018","unstructured":"Kametani F.; Hasegawa M.; Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer\u2019s Disease. Front Neurosci 2018,12(25),25","journal-title":"Front Neurosci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bcp.2012.12.007","volume":"86","author":"Popp J.","year":"2013","unstructured":"Popp J.; Meichsner S.; K\u00f6lsch H.; Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer\u2019s disease. Biochem Pharmacol 2013,86(1),37-42","journal-title":"Biochem Pharmacol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.1073\/pnas.081620098","volume":"98","author":"Fassbender K.","year":"2001","unstructured":"Fassbender K.; Simons M.; Bergmann C.; Simvastatin strongly reduces levels of Alzheimer\u2019s disease \u03b2-amyloid peptides A\u03b242 and A\u03b240 in vitro and in vivo. Proc Natl Acad Sci 2001,98(10),5856-5861","journal-title":"Proc Natl Acad Sci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/ncb1313","volume":"7","author":"Grimm M.O.W.","year":"2005","unstructured":"Grimm M.O.W.; Grimm H.S.; P\u00e4tzold A.J.; Regulation of cholesterol and sphingomyelin metabolism by amyloid-\u03b2 and presenilin. Nat Cell Biol 2005,7(11),1118-1123","journal-title":"Nat Cell Biol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3233\/JAD-2011-110053","volume":"25","author":"Canepa E.","year":"2011","unstructured":"Canepa E.; Borghi R.; Vi\u00f1a J.; Cholesterol and amyloid-\u03b2: Evidence for a cross-talk between astrocytes and neuronal cells. J Alzheimers Dis 2011,25(4),645-653","journal-title":"J Alzheimers Dis"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1471-4159.2008.05415.x","volume":"106","author":"Thirumangalakudi L.","year":"2008","unstructured":"Thirumangalakudi L.; Prakasam A.; Zhang R.; High cholesterol-induced neuroinflammation and amyloid precursor protein pro-cessing correlate with loss of working memory in mice. J Neurochem 2008,106(1),475-485","journal-title":"J Neurochem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s12035-010-8099-3","volume":"41","author":"Ong W.Y.","year":"2010","unstructured":"Ong W.Y.; Kim J.H.; He X.; Chen P.; Farooqui A.A.; Jenner A.M.; Changes in brain cholesterol metabolome after excitotoxicity. Mol Neurobiol 2010,41(2-3),299-313","journal-title":"Mol Neurobiol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.mcn.2010.08.001","volume":"45","author":"Ullrich C.","year":"2010","unstructured":"Ullrich C.; Pirchl M.; Humpel C.; Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. Mol Cell Neurosci 2010,45(4),408-417","journal-title":"Mol Cell Neurosci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/NEN.0b013e318212f185","volume":"70","author":"Gl\u00f6ckner F.","year":"2011","unstructured":"Gl\u00f6ckner F.; Meske V.; L\u00fctjohann D.; Ohm T.G.; Dietary cholesterol and its effect on tau protein: A study in apolipoprotein E-deficient and P301L human tau mice. J Neuropathol Exp Neurol 2011,70(4),292-301","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"6411","DOI":"10.1016\/j.febslet.2005.10.024","volume":"579","author":"Rahman A.","year":"2005","unstructured":"Rahman A.; Akterin S.; Flores-Morales A.; High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice. FEBS Lett 2005,579(28),6411-6416","journal-title":"FEBS Lett"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1073\/pnas.0305799101","volume":"101","author":"Cutler R.G.","year":"2004","unstructured":"Cutler R.G.; Kelly J.; Storie K.; Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer\u2019s disease. Proc Natl Acad Sci 2004,101(7),2070-2075","journal-title":"Proc Natl Acad Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jnutbio.2016.03.002","volume":"38","author":"Belkouch M.","year":"2016","unstructured":"Belkouch M.; Hachem M.; Elgot A.; The pleiotropic effects of omega-3 docosahexaenoic acid on the hallmarks of Alzheimer\u2019s dis-ease. J Nutr Biochem 2016,38,1-11","journal-title":"J Nutr Biochem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.3390\/ijerph16111995","volume":"16","author":"Sarrafpour S.","year":"2019","unstructured":"Sarrafpour S.; Ormseth C.; Chiang A.; Arakaki X.; Harrington M.; Fonteh A.; Lipid metabolism in late-onset Alzheimer\u2019s disease differs from patients presenting with other dementia phenotypes. Int J Environ Res Public Health 2019,16(11),1995","journal-title":"Int J Environ Res Public Health"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100519","volume":"9","author":"Fonteh A.N.","year":"2014","unstructured":"Fonteh A.N.; Cipolla M.; Chiang J.; Arakaki X.; Harrington M.G.; Human cerebrospinal fluid fatty acid levels differ between supernatant fluid and brain-derived nanoparticle fractions, and are altered in Alzheimer\u2019s disease. PLoS One 2014,9(6)","journal-title":"PLoS One"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1089\/ars.2011.3895","volume":"15","author":"Carrano A.","year":"2011","unstructured":"Carrano A.; Hoozemans J.J.M.; van der Vies S.M.; Rozemuller A.J.M.; van Horssen J.; de Vries H.E.; Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal 2011,15(5),1167-1178","journal-title":"Antioxid Redox Signal"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.nbd.2016.09.015","volume":"107","author":"de Wit N.M.","year":"2017","unstructured":"de Wit N.M.; Vanmol J.; Kamermans A.; Hendriks J.J.A.; de Vries H.E.; Inflammation at the blood-brain barrier: The role of liver X receptors. Neurobiol Dis 2017,107,57-65","journal-title":"Neurobiol Dis"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fnagi.2019.00146","volume":"11","author":"Edwards G.A.","year":"2019","unstructured":"Edwards G.A.; Gamez N.; Escobedo G.; Calderon O.; Moreno-Gonzalez I.; Modifiable risk factors for Alzheimer\u2019s disease. Front Aging Neurosci 2019,11,146","journal-title":"Front Aging Neurosci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"Nakamura A.","year":"2018","unstructured":"Nakamura A.; Kaneko N.; Villemagne V.L.; High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature 2018,554(7691),249-254","journal-title":"Nature"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1172\/JCI10498","volume":"106","author":"Shibata M.","year":"2000","unstructured":"Shibata M.; Yamada S.; Kumar S.R.; Clearance of Alzheimer\u2019s amyloid-\u03b21-40 peptide from brain by LDL receptor\u2013related protein-1 at the blood-brain barrier. J Clin Invest 2000,106(12),1489-1499","journal-title":"J Clin Invest"},{"key":"ref=35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001358","volume":"19","author":"Lam V.","year":"2021","unstructured":"Lam V.; Takechi R.; Hackett M.J.; Synthesis of human amyloid restricted to liver results in an Alzheimer disease\u2013like neurodegenera-tive phenotype. PLoS Biol 2021,19(9)","journal-title":"PLoS Biol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1074\/jbc.274.1.305","volume":"274","author":"Postic C.","year":"1999","unstructured":"Postic C.; Shiota M.; Niswender K.D.; Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem 1999,274(1),305-315","journal-title":"J Biol Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0022-2275(20)41379-3","volume":"33","author":"Endo A.","year":"1992","unstructured":"Endo A.; The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992,33(11),1569-1582","journal-title":"J Lipid Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.atherosclerosissup.2004.08.033","volume":"5","author":"Endo A.","year":"2004","unstructured":"Endo A.; The origin of the statins. Atheroscler Suppl 2004,5(3),125-130","journal-title":"Atheroscler Suppl"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.1038\/s41467-018-07590-3","volume":"9","author":"Jiang S.Y.","year":"2018","unstructured":"Jiang S.Y.; Li H.; Tang J.J.; Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol. Nat Commun 2018,9(1),5138","journal-title":"Nat Commun"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","volume":"29","author":"Goldstein J.L.","year":"2009","unstructured":"Goldstein J.L.; Brown M.S.; The LDL Receptor. Arterioscler Thromb Vasc Biol 2009,29(4),431-438","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"701","DOI":"10.4103\/0250-474X.49087","volume":"70","author":"Aravindan R.","year":"2008","unstructured":"Aravindan R.; Viruthagiri T.; Seenivasan A.; Subhagar S.; Microbial production and biomedical applications of lovastatin. Indian J Pharm Sci 2008,70(6),701-709","journal-title":"Indian J Pharm Sci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1001\/archneurol.2011.242","volume":"68","author":"Shepardson N.E.","year":"2011","unstructured":"Shepardson N.E.; Shankar G.M.; Selkoe D.J.; Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recom-mendations. Arch Neurol 2011,68(11),1385-1392","journal-title":"Arch Neurol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1001\/archneur.57.10.1439","volume":"57","author":"Wolozin B.","year":"2000","unstructured":"Wolozin B.; Kellman W.; Ruosseau P.; Celesia G.G.; Siegel G.; Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000,57(10),1439-1443","journal-title":"Arch Neurol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1212\/01.wnl.0000319647.15752.7b","volume":"71","author":"Cramer C.","year":"2008","unstructured":"Cramer C.; Haan M.N.; Galea S.; Langa K.M.; Kalbfleisch J.D.; Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008,71(5),344-350","journal-title":"Neurology"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","volume":"74","author":"Feldman H.H.","year":"2010","unstructured":"Feldman H.H.; Doody R.S.; Kivipelto M.; Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010,74(12),956-964","journal-title":"Neurology"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0024-3205(99)00199-X","volume":"65","author":"Moghadasian M.H.","year":"1999","unstructured":"Moghadasian M.H.; Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Life Sci 1999,65(13),1329-1337","journal-title":"Life Sci"},{"key":"ref=47","volume":"2015","author":"Adams S.P.","year":"2015","unstructured":"Adams S.P.; Tsang M.; Wright J.M.; Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev 2015,2015(3)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=48","author":"Feingold K.R.","year":"2000","unstructured":"Feingold K.R.; Cholesterol Lowering Drugs. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Eds. Endotext. South Dartmouth (MA): MDText.com, Inc. 2000"},{"key":"ref=49","author":"McIver L.A.","year":"2022","unstructured":"McIver L.A.; Siddique M.S.;  AtorvastatinStatPearls 2022","journal-title":"AtorvastatinStatPearls"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/WAD.0b013e3181a80242","volume":"23","author":"Sabbagh M.N.","year":"2009","unstructured":"Sabbagh M.N.; Thind K.; Sparks D.L.; On cholesterol levels and statins in cognitive decline and Alzheimer disease: progress and setbacks. Alzheimer Dis Assoc Disord 2009,23(4),303-305","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/jama.2010.1995","volume":"305","author":"Yaffe K.","year":"2011","unstructured":"Yaffe K.; Weston A.; Graff-Radford N.R.; Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 2011,305(3),261-266","journal-title":"JAMA"},{"key":"ref=52","first-page":"1344","volume":"7","author":"Sun Y.","year":"2012","unstructured":"Sun Y.; Wang G.; Pan Z.; Chen S.; Systematic review of atorvastatin for the treatment of Alzheimer\u2019s disease. Neural Regen Res 2012,7(17),1344-1351","journal-title":"Neural Regen Res"},{"key":"ref=53","author":"McGuinness B.","year":"2016","unstructured":"McGuinness B.; Craig D.; Bullock R.; Passmore P.; Statins for the prevention of dementia. Cochrane Database Syst Rev 2016(1)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/clc.22361","volume":"38","author":"Wanamaker B.L.","year":"2015","unstructured":"Wanamaker B.L.; Swiger K.J.; Blumenthal R.S.; Martin S.S.; Cholesterol, statins, and dementia: what the cardiologist should know. Clin Cardiol 2015,38(4),243-250","journal-title":"Clin Cardiol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.mam.2009.02.001","volume":"30","author":"Bj\u00f6rkhem I.","year":"2009","unstructured":"Bj\u00f6rkhem I.; Cedazo-Minguez A.; Leoni V.; Meaney S.; Oxysterols and neurodegenerative diseases. Mol Aspects Med 2009,30(3),171-179","journal-title":"Mol Aspects Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.bbadis.2006.10.014","volume":"1772","author":"Zhu X.","year":"2007","unstructured":"Zhu X.; Lee H.; Perry G.; Smith M.A.; Alzheimer disease, the two-hit hypothesis: An update. Biochim Biophys Acta Mol Basis Dis 2007,1772(4),494-502","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1196\/annals.1427.010","volume":"1147","author":"Pratic\u00f2 D.","year":"2008","unstructured":"Pratic\u00f2 D.; Evidence of oxidative stress in Alzheimer\u2019s disease brain and antioxidant therapy: lights and shadows. Ann N Y Acad Sci 2008,1147(1),70-78","journal-title":"Ann N Y Acad Sci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s00702-010-0438-z","volume":"117","author":"Heneka M.T.","year":"2010","unstructured":"Heneka M.T.; O\u2019Banion M.K.; Terwel D.; Kummer M.P.; Neuroinflammatory processes in Alzheimer\u2019s disease. J Neural Transm 2010,117(8),919-947","journal-title":"J Neural Transm"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJM199704243361704","volume":"336","author":"Sano M.","year":"1997","unstructured":"Sano M.; Ernesto C.; Thomas R.G.; A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer\u2019s disease. The Alzheimer\u2019s disease cooperative study. N Engl J Med 1997,336(17),1216-1222","journal-title":"N Engl J Med"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1080\/07853890310001294","volume":"35","author":"Nakagami H.","year":"2003","unstructured":"Nakagami H.; Jensen K.; Liao J.; A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mech-anisms. Ann Med 2003,35(6),398-403","journal-title":"Ann Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1161\/01.RES.0000269334.42814.d2","volume":"100","author":"Paumelle R.","year":"2007","unstructured":"Paumelle R.; Staels B.; Peroxisome proliferator-activated receptors mediate pleiotropic actions of statins. Circ Res 2007,100(10),1394-1395","journal-title":"Circ Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","volume":"45","author":"Liao J.K.","year":"2005","unstructured":"Liao J.K.; Laufs U.; Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005,45(1),89-118","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00401-008-0366-2","volume":"115","author":"Thal D.R.","year":"2008","unstructured":"Thal D.R.; Griffin W.S.T.; de Vos R.A.I.; Ghebremedhin E.; Cerebral amyloid angiopathy and its relationship to Alzheimer\u2019s disease. Acta Neuropathol 2008,115(6),599-609","journal-title":"Acta Neuropathol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/alzrt6","volume":"1","author":"Weller R.O.","year":"2009","unstructured":"Weller R.O.; Preston S.D.; Subash M.; Carare R.O.; Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res Ther 2009,1(2),6","journal-title":"Alzheimers Res Ther"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrn1387","volume":"5","author":"Iadecola C.","year":"2004","unstructured":"Iadecola C.; Neurovascular regulation in the normal brain and in Alzheimer\u2019s disease. Nat Rev Neurosci 2004,5(5),347-360","journal-title":"Nat Rev Neurosci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.amjhyper.2005.05.022","volume":"18","author":"Bayorh M.","year":"2005","unstructured":"Bayorh M.; Ganafa A.; Eatman D.; Walton M.; Feuerstein G.; Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension. Am J Hypertens 2005,18(11),1496-1502","journal-title":"Am J Hypertens"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/ana.410300206","volume":"30","author":"McKee A.C.","year":"1991","unstructured":"McKee A.C.; Kosik K.S.; Kowall N.W.; Neuritic pathology and dementia in alzheimer\u2019s disease. Ann Neurol 1991,30(2),156-165","journal-title":"Ann Neurol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1096\/fj.11-181297","volume":"25","author":"Rudrabhatla P.","year":"2011","unstructured":"Rudrabhatla P.; Jaffe H.; Pant H.C.; Direct evidence of phosphorylated neuronal intermediate filament proteins in Neuro Fibrillary Tangles (NFTs): Phosphoproteomics of Alzheimer\u2019s NFTs. FASEB J 2011,25(11),3896-3905","journal-title":"FASEB J"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"Jack C.R.","year":"2013","unstructured":"Jack C.R.; Knopman D.S.; Jagust W.J.; Tracking pathophysiological processes in Alzheimer\u2019s disease: An updated hypothetical mod-el of dynamic biomarkers. Lancet Neurol 2013,12(2),207-216","journal-title":"Lancet Neurol"},{"key":"ref=70","author":"Vergouwen M.D.","year":"2008","unstructured":"Vergouwen M.D.;  In: Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews York (UK) 2008","journal-title":"In: Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews York (UK)"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1161\/STROKEAHA.107.488791","volume":"39","author":"Vergouwen M.D.I.","year":"2008","unstructured":"Vergouwen M.D.I.; de Haan R.J.; Vermeulen M.; Roos Y.B.W.E.M.; Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke 2008,39(2),497-502","journal-title":"Stroke"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1161\/STROKEAHA.107.487090","volume":"38","author":"Sturgeon J.D.","year":"2007","unstructured":"Sturgeon J.D.; Folsom A.R.; Longstreth W.T.; Shahar E.; Rosamond W.D.; Cushman M.; Risk factors for intracerebral hemorrhage in a pooled prospective study. Stroke 2007,38(10),2718-2725","journal-title":"Stroke"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/(SICI)1097-4547(19981001)54:1<58:AID-JNR7>3.0.CO;2-G","volume":"54","author":"Michikawa M.","year":"1998","unstructured":"Michikawa M.; Yanagisawa K.; Apolipoprotein E4 induces neuronal cell death under conditions of suppressed de novo cholesterol syn-thesis. J Neurosci Res 1998,54(1),58-67","journal-title":"J Neurosci Res"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1046\/j.1460-9568.2003.02433.x","volume":"17","author":"Meske V.","year":"2003","unstructured":"Meske V.; Albert F.; Richter D.; Schwarze J.; Ohm T.G.; Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer\u2019s disease. Eur J Neurosci 2003,17(1),93-102","journal-title":"Eur J Neurosci"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"15280","DOI":"10.1038\/s41598-021-94803-3","volume":"11","author":"Jeong S.M.","year":"2021","unstructured":"Jeong S.M.; Shin D.W.; Yoo T.G.; Association between statin use and Alzheimer\u2019s disease with dose response relationship. Sci Rep 2021,11(1),15280","journal-title":"Sci Rep"},{"key":"ref=76","first-page":"631","volume":"32","author":"Ramkumar S.","year":"2016","unstructured":"Ramkumar S.; Raghunath A.; Raghunath S.; Statin therapy: Review of safety and potential side effects. Zhonghua Minguo Xinzangxue Hui Zazhi 2016,32(6),631-639","journal-title":"Zhonghua Minguo Xinzangxue Hui Zazhi"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/pds.3199","volume":"21","author":"Rowan C.G.","year":"2012","unstructured":"Rowan C.G.; Brunelli S.M.; Munson J.; Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospec-tive cohort study in The Health Improvement Network. Pharmacoepidemiol Drug Saf 2012,21(5),494-506","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2337\/diacare.24.8.1335","volume":"24","year":"2001","unstructured":"The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, ran-domized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001,24(8),1335-1341","journal-title":"Diabetes Care"},{"key":"ref=79","first-page":"298","volume":"10","author":"Sadeghi R.","year":"2014","unstructured":"Sadeghi R.; Asadpour-Piranfar M.; Asadollahi M.; Taherkhani M.; Baseri F.; The effects of different doses of atorvastatin on serum lipid profile, glycemic control, and liver enzymes in patients with ischemic cerebrovascular accident. ARYA Atheroscler 2014,10(6),298-304","journal-title":"ARYA Atheroscler"},{"key":"ref=80","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003350","volume":"5","author":"Jackevicius C.A.","year":"2016","unstructured":"Jackevicius C.A.; Tu J.V.; Krumholz H.M.; Comparative effectiveness of generic Atorvastatin and Lipitor \u00ae in patients hospitalized with an acute coronary syndrome. J Am Heart Assoc 2016,5(4)","journal-title":"J Am Heart Assoc"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"990","DOI":"10.2174\/156720512803251075","volume":"9","author":"Carlsson C.M.","year":"2012","unstructured":"Carlsson C.M.; Xu G.; Wen Z.; Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer\u2019s disease: A pilot study. Curr Alzheimer Res 2012,9(8),990-997","journal-title":"Curr Alzheimer Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/archneur.62.5.753","volume":"62","author":"Sparks D.L.","year":"2005","unstructured":"Sparks D.L.; Sabbagh M.N.; Connor D.J.; Atorvastatin for the treatment of mild to moderate Alzheimer disease: Preliminary results. Arch Neurol 2005,62(5),753-757","journal-title":"Arch Neurol"},{"key":"ref=83","unstructured":"To evaluate the safety and effectiveness of atorvastatin plus a cholinesterase inhibitor in AD Patients. Available from:"},{"key":"ref=84","unstructured":"(NIMH), The effect of short-term statin and NSAID treatment on CSF beta-amyloid. Available from:"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/acn3.51421","volume":"8","author":"Vogt N.M.","year":"2021","unstructured":"Vogt N.M.; Hunt J.F.V.; Ma Y.; Effects of simvastatin on white matter integrity in healthy middle\u2010aged adults. Ann Clin Transl Neurol 2021,8(8),1656-1667","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=86","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009792","volume":"8","author":"Gepner A.D.","year":"2019","unstructured":"Gepner A.D.; Lazar K.; Hulle C.V.; Korcarz C.E.; Asthana S.; Carlsson C.M.; Effects of simvastatin on augmentation index are transient: out-comes from a randomized controlled trial. J Am Heart Assoc 2019,8(20)","journal-title":"J Am Heart Assoc"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.3390\/jcm9062004","volume":"9","author":"Dhuri K.","year":"2020","unstructured":"Dhuri K.; Bechtold C.; Quijano E.; Antisense oligonucleotides: An emerging area in drug discovery and development. J Clin Med 2020,9(6),2004","journal-title":"J Clin Med"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","volume":"42","author":"Bennett C.F.","year":"2019","unstructured":"Bennett C.F.; Krainer A.R.; Cleveland D.W.; Antisense oligonucleotide therapies for neurodegenerative diseases. Annu Rev Neurosci 2019,42(1),385-406","journal-title":"Annu Rev Neurosci"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.freeradbiomed.2013.11.014","volume":"67","author":"Farr S.A.","year":"2014","unstructured":"Farr S.A.; Ripley J.L.; Sultana R.; Antisense oligonucleotide against GSK-3\u03b2 in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease. Free Radic Biol Med 2014,67,387-395","journal-title":"Free Radic Biol Med"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/5380346","volume":"2020","author":"Oxford A.E.","year":"2020","unstructured":"Oxford A.E.; Stewart E.S.; Rohn T.T.; Clinical trials in Alzheimer\u2019s disease: A hurdle in the path of remedy. Int J Alzheimers Dis 2020,2020,1-13","journal-title":"Int J Alzheimers Dis"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMp1700446","volume":"376","author":"Gellad W.F.","year":"2017","unstructured":"Gellad W.F.; Kesselheim A.S.; Accelerated approval and expensive drugs-a challenging combination. N Engl J Med 2017,376(21),2001-2004","journal-title":"N Engl J Med"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756286418776932","volume":"11","author":"Wurster C.D.","year":"2018","unstructured":"Wurster C.D.; Ludolph A.C.; Antisense oligonucleotides in neurological disorders. Ther Adv Neurol Disord 2018,11,1-19","journal-title":"Ther Adv Neurol Disord"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"133","DOI":"10.12997\/jla.2022.11.2.133","volume":"11","author":"Lee J.","year":"2022","unstructured":"Lee J.; Park S.; Kim Y.; Kim H.M.; Oh C.M.; Exploring the genetic associations between the use of statins and Alzheimer\u2019s disease. J Lipid Atheroscler 2022,11(2),133-146","journal-title":"J Lipid Atheroscler"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527322666221005124808","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/209614\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527322666221005124808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T11:16:54Z","timestamp":1694603814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/209614\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":93,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527322666221005124808","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-06-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}